1. Home
  2. GRRR vs CBIO Comparison

GRRR vs CBIO Comparison

Compare GRRR & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gorilla Technology Group Inc.

GRRR

Gorilla Technology Group Inc.

HOLD

Current Price

$13.17

Market Cap

311.9M

Sector

Technology

ML Signal

HOLD

CBIO

Crescent Biopharma Inc. Common Stock

HOLD

Current Price

$13.09

Market Cap

252.6M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
GRRR
CBIO
Founded
2001
2003
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
311.9M
252.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
GRRR
CBIO
Price
$13.17
$13.09
Analyst Decision
Buy
Strong Buy
Analyst Count
1
5
Target Price
$18.00
$25.60
AVG Volume (30 Days)
1.2M
56.4K
Earning Date
11-17-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$99,747,682.00
N/A
Revenue This Year
$36.14
N/A
Revenue Next Year
$27.83
N/A
P/E Ratio
N/A
N/A
Revenue Growth
47.86
N/A
52 Week Low
$5.75
$9.81
52 Week High
$44.15
$21.40

Technical Indicators

Market Signals
Indicator
GRRR
CBIO
Relative Strength Index (RSI) 40.21 47.84
Support Level $13.00 $12.76
Resistance Level $13.83 $15.40
Average True Range (ATR) 1.04 0.73
MACD 0.13 0.05
Stochastic Oscillator 27.55 17.83

Price Performance

Historical Comparison
GRRR
CBIO

About GRRR Gorilla Technology Group Inc.

Gorilla Technology Group Inc is engaged in providing information, software, and data processing services. It is a provider of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology (OT) security solutions and services. Its reportable segments are video IoT and security convergence and Other segments.

About CBIO Crescent Biopharma Inc. Common Stock

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: